Neuritek is developing the first mechanisms-based treatment for PTSD.
Neuritek's treatment approach activates the body's own cannabinoid system function.
Our advanced research has shown that activating the body's own cannabinoid system function offers a unique opportunity to treat PTSD and has the potential to improve patient outcomes.
PTSD will develop in 20% of trauma survivors, with about 1 in 3 developing chronic PTSD.
Between 1.5% to 3.0% of the population have PTSD in a given year, resulting in about 8 million people with PTSD in the United States. It is estimated that worldwide approximatley 354 million war survivors suffer from PTSD, and this number increases significantly considering other causes of severe trauma exposure.
Current available treatments include different forms of psychotherapy or medications or their combination. However, patients and clinicians often agree that these treatments are inadequate in addressing the wide range of symptoms in PTSD. Importantly, these treatments often do not control the exaggerated suicide risk, and increased medical risks, resulting in decreased life expectancy in PTSD.